Literatur
-
1
Heintz A P, Odicino F, Maisonneuve P et al.
Carcinoma of the ovary. FIGO 6th annual report on the results of treatment in gynecological cancer.
Int J Gynaecol Obstet.
2006;
95
161-192
-
2
Kobayashi H, Yamado Y, Sado T et al.
A randomized study of screening for ovarian cancer: a multicenter study in Japan.
Int J Gynecol Cancer.
2008;
18
414-420
-
3
Kuschel B, Hauenstein E, Kiechle M et al.
Hereditary breast and ovarian cancer – current clinical guidelines in Germany.
Breast Care.
2006;
1
8-14
-
4
Antoniou A, Pharoah P D, Narod S et al.
Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in case series unselected for family history: a combined analysis of 22 studies.
Am J Hum Genet.
2003;
72
1117-1130
-
5
Kauff N D, Satagopan J M, Robson M E et al.
Risk-reducing salpingo-oophorectomy in women with a BRCA1 or BRCA2 mutation.
N Engl J Med.
2002;
346
1609-1615
-
6
Narod S A, Risch H, Moslehi R et al.
Oral contraceptives and the risk of hereditary ovarian cancer. Hereditary Ovarian Cancer Clinical Study Group.
N Engl J Med.
1998;
339
424-428
-
7
Narod S A, Dubé M P, Klijn J et al.
Oral contraceptives and the risk of breast cancer in BRCA1 and BRCA2 mutation carriers.
J Natl Cancer Inst.
2002;
94
1773-1779
-
8 Manual Maligne Ovarialtumoren. Anhang II Operationsprotokoll. 8. Aufl. W. München: Zuckerschwerdt; 2007: 107
-
9
Trimbos J B.
Staging of early ovarian cancer and the impact of lymph node sampling.
Int J Gynecol Cancer.
2000;
10
8-10
-
10
Trimbos J B, Vergote I, Bolis G et al.
Impact of adjuvant chemotherapy and surgical staging in early-stage ovarian carcinoma: European Organization for Research and Treatment of Cancer-Adjuvant Chemotherapy in Ovarian Neoplasm trial.
J Natl Cancer Inst.
2003;
95
113-125
-
11 Kommission Ovar der AGO. S2k-Leitlinie für die Diagnostik und Therapie maligner Ovarialtumoren.
http://www.ago-online.org/download/ovar_s2k_leitlinie_maligner_tumoren.pdf
-
12
Bristow R E, Tomacruz R S, Armstrong D K et al.
Survival effect of maximal cytoreductive surgery for advanced ovarian carcinoma during the platinum era: a meta-analysis.
J Clin Oncol.
2002;
20
1248-1259
-
13
Panici P B, Maggioni A, Hacker N et al.
Systematic aortic and pelvic lymphadenectomy versus resection of bulky nodes only in optimally debulked advanced ovarian cancer: a randomized clinical trial.
J Natl Cancer Inst.
2005;
97
560-566
-
14
Bristow R E, Eisenhauer E L, Santillan A et al.
Delaying the primary surgical effort for advanced ovarian cancer: a systematic review of neoadjuvant chemotherapy and interval cytoreduction.
Gynecol Oncol.
2007;
104
480-490
-
15
Trimbos J B, Parmar M, Vergote I et al.
International collaborative ovarian neoplasm trial 1 and adjuvant chemotherapy in ovarian neoplasm trial: two parallel randomized phase III trials of adjuvant chemotherapy in patients with early-stage ovarian carcinoma.
J Natl Cancer Inst.
2003;
95
105-112
-
16
Du Bois A, Weber B, Rochon J et al.
Addition of epirubicin as a third drug to carboplatin-paclitaxel in first-line treatment of advanced ovarian cancer: a prospectively randomized gynecologic cancer intergroup trial by the Arbeitsgemeinschaft Gynaekologische Onkologie Ovarian Cancer Study Group and the Groupe d'Investigateurs Nationaux pour l’Etude des Cancers Ovariens.
J Clin Oncol.
2006;
24
1127-1135
-
17
Pfister J, Weber R, Reuss A et al.
Randomized phase III trial of topotecan following carboplatin and paclitaxel in first-line treatment of advanced ovarian cancer: a gynecologic cancer intergroup trial of the AGO-OVAR and GINECO.
J Natl Cancer Inst.
2006;
98
1036-1045
-
18
Gore M, Du Bois A, Vergote I.
Intraperitoneal chemotherapy in ovarian cancer remains experimental.
J Clin Oncol.
2006;
24
4528-4530
-
19
Harter P, Du Bois A, Hahman M et al.
Surgery in recurrent ovarian cancer: the Arbeitsgemeinschaft Gynaekologische Onkologie (AGO) DESKTOP OVAR trial.
Ann Surg Oncol.
2006;
13
1702-1710
-
20
Rose P G, Blessing J A, Mayer A R et al.
Prolonged oral etoposide as second-line therapy for platinum-resistant and platinum-sensitive ovarian carcinoma: a Gynecologic Oncology Group study.
J Clin Oncol.
1998;
16
405-410
-
21
Lund B, Hansen O, Theilade K et al.
Phase II study of gemcitabine (2′,2′-difluorodeoxycytidine) in previously treated ovarian cancer patients.
J Natl Cancer Inst.
1994;
86
1530-1533
-
22
Sorensen P, Hoyer M, Jakobsen A et al.
Phase II study of vinorelbine in the treatment of platinum-resistant ovarian carcinoma.
Gynecol Oncol.
2001;
81
58-62
-
23
Markman M, Hakes T, Reichman B et al.
Ifosfamide and mesna in previously treated advanced epithelial ovarian cancer: activity in platinum-resistant disease.
J Clin Oncol.
1992;
10
243-248
-
24
Parmar M K, Lederman J A, Colombo N et al.
Paclitaxel plus platinum-based chemotherapy versus conventional platinum-based chemotherapy in women with relapsed ovarian cancer: the ICON4 / AGO-OVAR-2.2 trial.
Lancet.
2003;
361
2099-2106
-
25
Pfisterer J, Plante M, Vergote I et al.
Gemcitabine plus carboplatin compared with carboplatin in patients with platinum-sensitive recurrent ovarian cancer: an intergroup trial of the AGO-OVAR, the NCIC CTG, and the EORTC GCG.
J Clin Oncol.
2006;
24
4699-4707
-
26
Smyth J F, Gourley C, Walker G et al.
Antiestrogen therapy is active in selected ovarian cancer cases: the use of letrozole in estrogen receptor-positive patients.
Clin Cancer Res.
2007;
13
3617-3622
-
27
Markman M, Iseminger K A, Hatch K D et al.
Tamoxifen in platinum-refractory ovarian cancer: a Gynecologic Oncology Group Ancillary Report.
Gynecol Oncol.
1996;
62
4-6
-
28 Wallwiener D, Jonat W, Kreienberg R , et al. Atlas der gynäkologischen Operationen. 7., vollst. überarb. Aufl. Stuttgart: Thieme; 2008
Prof. Dr. T. Fehm
Frauenklinik Tübingen
Calwer Str. 7
72076 Tübingen
eMail: tanja.fehm@med.uni-tuebingen.de
